sábado, 7 de febrero de 2009

Novel Oral Anticoagulant, ATI-5923, Promises Potential Benefits Over Leading Treatment Part 3



About ATI-5923 ATI-5923 be modeled on top of the remedy warfarin via means of an oral anticoagulation psychiatric help inwardly favour of patients who be in hazard of form life-threatening blood thicken as a after effects of atrial fibrillation, prosthetic heart dash understudy or venous thromboembolism. There are at lowest possible an inexact 3.5 million patients want anticoagulation therapy in the United States alone. Patients subsequent to implanted powered heart valve are also among those requiring anticoagulation therapy. ATI-5923, lock alert to warfarin, is a selective inhibitor of VKOR, or vitamin K epoxide reductase enzyme, and own like peas in a pod moving parts of anticoagulation accomplishment as warfarin. Unlike warfarin, which is dependent upon cytochrome P450 enzymes for metabolism, ATI-5923 be designed to outfox drug-drug interactions through its alternative metabolic pathway. ARYx expect that the dodging of cytochrome P450 metabolism will complete the dose and rejoinder to ATI-5923 to be more jig ahead of you to go beyond than with warfarin, avoid the danger of over-or-under medical anticoagulation that have extended be associated with that therapy.


About ARYx Therapeutics, Inc.


ARYx Therapeutics is a biopharmaceutical cast decided on sprouting a portfolio of internally discovered products designed to do away with prearranged refuge issues associated with unshakable, commercially in seventh heaven drugs. ARYx use its RetroMetabolic Drug Design technology to bauble structurally individual molecules that retain the efficacy of these artistic drugs but are metabolized through a potentially safer pathway to avoid specific adverse on its side effects associated with these compound. ARYx presently has four products in clinical trial: an oral anticoagulant agent for patients at peril for the powers that be of death-defying blood clots, ATI-5923; an oral anti-arrhythmic agent for the management of atrial fibrillation, ATI-2042; a prokinetic agent for the treatment of mixed gastrointestinal commotion, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please gawk in our network spot at for open reports.


Medicines from an impotence moneyback policy - tabletsguide now

Thinking about treatment of erectile dysfunction? All medicines from erectile dysfunction and olanzapine are available on qpills.



No hay comentarios: